Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8614271 | 1.00 | CYP11B1 (0.38) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| Hydrochloric Acid SCHEMBL8614165 | 0.98 | CYP11B1 (0.37) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL12501555 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKCNH2 | |
| SCHEMBL16290335 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKDM1B | |
| SCHEMBL31034383 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKCNH2 | |
| SCHEMBL16290385 | 0.81 | HTR2A (0.34) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL16290348 | 0.81 | CYP11B1 (0.33) | CYP11B1CYP11B2EPAS1KDM1AANPEP | |
| SCHEMBL23136253 | 0.76 | HTR2A (0.36) | HTR2AHTR2C | |
| SCHEMBL326748 | 0.76 | CYP11B1 (0.38) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL1150762 | 0.72 | DRD2 (0.49) | CYP11B1CYP11B2HTR2CANPEPDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688756-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206345-A1 | QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | CYP11B1 2469/4885CYP11B2 2270/4885HTR2A 128/4885 |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | CYP11B1 324/4885CYP11B2 213/4885HTR2A 763/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CYP11B1 25/4885CYP11B2 64/4885HTR2A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.